tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Newron Pharma downgraded to Add from Buy at Baader Helvea

Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Disclaimer & DisclosureReport an Issue

1